Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky

Emergent BioSolutions reported approximately $97 million in adjusted EBITDA for the quarter. The same period included a $191.3 million non-cash NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations. NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Emergent...